Laurie Toich, Assistant Editor

Ozanimod met all primary and secondary endpoints of the RADIANCE trial in patients with relapsing multiple sclerosis.

Changes in the Rap1 gene associated with leptin resistance, which promotes obesity.

Onduo use technological advances to enhance management of diabetes.

Onduo will use new technology and professional care to improve the lives of patients with diabetes.

Top news of the day from across the healthcare landscape.

Researchers explore the effects of advertising on customer requests for psychiatric medication and proper treatment.

Ocrevus (ocrelizumab) effective in patients with relapsing and primary progressive multiple sclerosis.

Esketamine offered depression symptom relief in as little as 2 hours.

Perampanel is an antiepileptic that inhibits AMPA receptors, but can cause side effects in patients.

Top news of the day from across the healthcare landscape.

Refunds will be offered to plan sponsors if a patient discontinues a preferred anti-inflammatory drug within 90 days.

Exondys 51 is the first drug approved by the FDA to treat Duchenne muscular dystrophy.

Savings program offers $0 co-pays and customer support on antiepileptic treatment.

Approximately 4.3 million people reported nonmedical use of prescription pain killers in 2014.

Top news of the day from across the healthcare landscape.

Drugs targeting allosteric binding sites may prevent side effects associated with heart medications.

Neutron crystallography may lead to new structure-based drug design.

Nasal cavity hydration may be an important factor preventing nosebleeds in patients with hemorrhagic telangiectasia.

Final requirements issued that address the health of safety of Medicare and Medicaid recipients during an emergency.

Nutra Pharma and Omnia Biologics will partner to create pediatric multiple sclerosis treatment derived from cobra venom.

Allergan plans to acquire Vitae Pharmaceuticals and their experimental dermatology drugs.

Oral administration of insulin may be possible with Cholestosomes.

Protocadherin 10 may affect social interaction in patients with autism spectrum disorder.

Trevo devices should be used after treatment with tissue plasminogen activator in patients with an ischemic stroke.

A streamlined process for drug manufacturing may reduce prescription medication costs.

Bacteria found in saliva could expand treatment options for patients who are gluten intolerant from celiac disease.

The Yellow Card Scheme lacks detailed data about adverse drug reactions in young children.

A new phase of the Alzheimer’s Disease Neuroimaging Initiative will start in the fall of 2016.

Bristol-Myers Squibb employees will cycle across the US to raise awareness for cancer research.

The Anthem-Cigna merger could drive down competition and raise costs in New York’s insurance market.